Compound 21 for Preeclampsia
Trial Summary
If you are currently taking antihypertensive or cholesterol-lowering medications, you cannot participate in this trial. The protocol does not specify about other medications, so it's best to discuss with the trial team.
Research suggests that targeting the angiotensin receptors, like those affected by Compound 21, may have potential in treating preeclampsia. The angiotensin system is involved in blood pressure regulation, and variations in angiotensin receptor genes have been linked to preeclampsia, indicating that drugs affecting these receptors could be beneficial.
12345Compound 21, also known as an Angiotensin II Type 2 Receptor Agonist, has been studied for its ability to lower blood pressure, but specific safety data for humans is not detailed in the available research.
12467Compound 21 is unique because it targets GPCRs (G protein-coupled receptors), which are promising candidates for treating preeclampsia, unlike other treatments that focus on different pathways. This approach could offer a new way to manage the condition by addressing specific receptor targets involved in the disease.
12458Eligibility Criteria
This trial is for women aged 18-45 who experienced preeclampsia between 12 weeks and 5 years ago. It's also open to those who had healthy pregnancies. Participants should not be currently pregnant, planning pregnancy, have a history of hypertension or metabolic disease before pregnancy, use tobacco, or take certain medications like antihypertensives or statins.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo intradermal microdialysis for the local delivery of compound 21 and L-NAME to the cutaneous microvasculature
Follow-up
Participants are monitored for changes in microvascular blood flow response and angiotensin receptor expression